These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32662933)

  • 21. Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder.
    Cuomo A; Barillà G; Cattolico M; Pardossi S; Mariantoni E; Koukouna D; Carmellini P; Fagiolini A
    Expert Rev Neurother; 2024 May; 24(5):465-476. PubMed ID: 38536761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vortioxetine overdose in a suicidal attempt: A case report.
    Mazza MG; Rossetti A; Botti ER; Clerici M
    Medicine (Baltimore); 2018 Jun; 97(25):e10788. PubMed ID: 29923970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
    Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
    Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
    Borhannejad F; Shariati B; Naderi S; Shalbafan M; Mortezaei A; Sahebolzamani E; Saeb A; Hosein Mortazavi S; Kamalzadeh L; Aqamolaei A; Ali Noorbala A; Namazi-Shabestari A; Akhondzadeh S
    J Clin Pharm Ther; 2020 Aug; 45(4):804-811. PubMed ID: 32420649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restless Legs Syndrome Related to Vortioxetine: A Case Report.
    Romigi A; Vitrani G; Caccamo M; Centonze D
    J Clin Psychopharmacol; 2019; 39(5):514-516. PubMed ID: 31433340
    [No Abstract]   [Full Text] [Related]  

  • 29. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vortioxetine: a new antidepressant to treat depressive episodes].
    Colle R; Corruble E
    Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness.
    Baldwin DS; Necking O; Schmidt SN; Ren H; Reines EH
    J Affect Disord; 2022 Aug; 311():588-594. PubMed ID: 35597471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder.
    Vieta E; Loft H; Florea I
    Eur Neuropsychopharmacol; 2017 Sep; 27(9):877-884. PubMed ID: 28693903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
    Dubovsky SL
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):759-66. PubMed ID: 24684240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
    Papalexi E; Galanopoulos A; Kontis D; Markopoulou M; Balta G; Karavelas E; Panagiotidis P; Vlachos T; Ettrup A
    BMC Psychiatry; 2022 Aug; 22(1):548. PubMed ID: 35962369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults.
    Matsuno K; Nakamura K; Aritomi Y; Nishimura A
    Clin Pharmacol Drug Dev; 2018 Mar; 7(3):319-331. PubMed ID: 28941196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vortioxetine for the treatment of major depression.
    Dhir A
    Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
    Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
    J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
    Jacobsen P; Zhong W; Xu R; Nomikos G
    J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.